Bris Johnson used his first new £1 MILLION a year Daily Mail column to promote the drug Ozempic despite him still being morbidly obese.
The safety assessment will look at Wegovy, Saxenda and similar drugs, such as Ozempic, that help curb appetite.
Product leaflets already list suicidal thoughts as a possible side effect.
Suicidal behaviour is not currently listed for these prescription drugs.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), which is conducting the review, will consider whether other treatments in same broader category of medicines, glucagon-like peptide-1 (GLP-1) receptor agonists, also need assessing.
But initially, it will assess only the risks of using weight-loss medication that contains either semaglutide or liraglutide.
An EMA official said: “The review is being carried out in the context of a signal procedure raised by the Icelandic Medicines Agency, following three case reports.
“A signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation.
“The case reports included two cases of suicidal thoughts – one following the use of Saxenda and one after Ozempic.
“One additional case reported thoughts of self-injury with Saxenda.
“The EMA will communicate further when more information becomes available.”
Lead Correspondent | David Clews is the Lead Correspondent for UNN, with over 20 years of political/campaigning experience and a wealth of social media and communication skills David gets to the heart of what is really important to the real people of the UK.
Keep up to date with all of David & UN’s work by linking up with us on our Social Media Channels by Clicking Here Now: https://unitynewsnetwork.co.uk/our-social-media-links/
